Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial

BACKGROUND: CSL112 is a new formulation of human apolipoprotein A-I (apoA-I) being developed to reduce cardiovascular events following acute coronary syndrome. This phase 2a, randomized, double-blind, multicenter, dose-ranging trial represents the first clinical investigation to assess the safety an...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Am Heart Assoc
Prif Awduron: Tricoci, Pierluigi, D’Andrea, Denise M, Gurbel, Paul A, Yao, Zhenling, Cuchel, Marina, Winston, Brion, Schott, Robert, Weiss, Robert, Blazing, Michael A, Cannon, Louis, Bailey, Alison, Angiolillo, Dominick J, Gille, Andreas, Shear, Charles L, Wright, Samuel D, Alexander, John H
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley & Sons, Ltd 2015
Pynciau:
Original Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4599471/
https://ncbi.nlm.nih.gov/pubmed/26307570
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.115.002171
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg